Sienna biopharmaceuticals, inc. (SNNA)
Income statement / TTM
Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Sep'16Jun'16
Operating expenses:
Research and development

26,771

35,097

45,705

51,592

50,283

47,535

38,547

30,484

23,765

16,851

0

0

0

General and administrative

24,705

24,822

28,155

24,906

21,136

20,922

19,508

18,087

15,143

12,768

0

0

0

(Gain) loss on remeasurement of contingent consideration

0

-

-

-

0

-

-

-

-

-

-

-

-

Impairment of goodwill and in-process research and development

0

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

49,371

59,919

73,860

76,498

70,719

68,457

58,055

48,571

38,908

29,619

0

0

0

Loss from operations

-49,371

-59,919

-73,860

-76,498

-70,719

-68,457

-58,055

-48,571

-38,908

-29,619

0

0

0

Reorganization items

0

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expense), net

-1,195

-856

1,110

3,027

5,315

3,371

270

-2,264

-4,769

-2,509

0

0

0

Net loss before income taxes

0

-

-

-

0

-

-

-

-

-

-

-

-

Net loss before taxes

-

-

-

-

-

-

-

-50,835

-43,677

-32,128

0

0

0

Income tax benefit

0

-

-

-

-

-

-

-290

0

0

0

-

-

Net loss

-47,951

-60,775

-72,750

-73,471

-65,326

-64,923

-57,541

-50,545

-43,465

-32,001

0

0

0

Other comprehensive income (loss):
Cumulative translation adjustment

-2,551

-1,478

-4,558

-2,171

-845

1,139

6,339

5,736

0

0

0

-

-

Comprehensive loss

-50,502

-62,253

-77,308

-75,642

-66,171

-63,784

-51,202

-44,809

-38,400

-28,524

0

0

0

Per share information:
Net loss, basic and diluted

-0.13

-0.27

-0.67

-0.92

-0.82

-1.00

-0.85

7.73

-1.12

-6.50

-5.30

-2.42

-2.91

Weighted average shares outstanding, basic and diluted

30,726

30,354

24,606

20,810

20,473

20,289

20,228

20,381

14,674

1,978

1,907

1,697

1,693